Business Performance - The company recorded a revenue of approximately HKD 655,792,000 for the year ended December 31, 2020, a significant increase of about 10.07 times compared to HKD 59,214,000 for the year ended December 31, 2019[17]. - The revenue from the medical laboratory testing and health check services segment increased significantly from approximately HKD 53,551,000 in 2019 to approximately HKD 646,748,000 in 2020, representing a growth of 1,108%[22]. - The gross profit for 2020 was approximately HKD 339,082,000, up from approximately HKD 22,373,000 in 2019, an increase of approximately HKD 316,709,000[26]. - The gross profit margin improved to approximately 51.71% in 2020, up from approximately 37.78% in 2019, an increase of about 13.93 percentage points[26]. - The total revenue from the insurance brokerage services segment was approximately HKD 6,875,000 in 2020, compared to HKD 2,402,000 in 2019, marking a significant increase[23]. - The company recorded a net profit of approximately HKD 167,623,000 in 2020, reversing a net loss of approximately HKD 107,483,000 in 2019[32]. COVID-19 Response - The company completed over 1,700,000 COVID-19 tests, with a peak daily testing capacity of 230,000 samples[1]. - The establishment of the mobile laboratory at Hong Kong International Airport provided rapid RT-PCR testing services, reducing passenger wait times from 8-12 hours to 2-3 hours[1]. - The company established a laboratory and an additional temporary laboratory with 16 air membranes in Hong Kong to provide COVID-19 testing services[22]. - The company entered into a service agreement for COVID-19 testing services, with a transaction value of HKD 145,393,461.77[42]. Biotechnology Developments - Shanghai Longyao Biotechnology Co., a non-wholly owned subsidiary, achieved a milestone with its LY007 cell injection, becoming the first CAR-T product targeting CD20 to receive clinical application approval in China[8]. - The company aims to continue developing its biotechnology platform and provide high-quality immune cell therapy technologies[12]. - The company aims to diversify its testing business and expedite clinical trials for CAR-T products, with a focus on the Greater Bay Area healthcare market[45]. Financial Management - Administrative expenses rose to approximately HKD 132,489,000 in 2020, an increase of about 40.78% from approximately HKD 94,111,000 in 2019[30]. - Interest income from the lending business was approximately HKD 1,300,000 in 2020, down from HKD 1,688,000 in 2019[24]. - The financing costs increased to approximately HKD 6,498,000 in 2020, compared to HKD 1,692,000 in 2019, primarily due to the issuance of convertible bonds[31]. - The company strengthened its capital base through the issuance of convertible bonds, which will not immediately dilute existing shareholders' equity[36]. Corporate Governance - The company adhered to the GEM Listing Rules Appendix 15 Corporate Governance Code during the fiscal year ending December 31, 2020[87]. - The board consists of six executive directors and three independent non-executive directors, reflecting a mix of skills and experience[89]. - The company has implemented corporate governance measures focusing on integrity, quality of information disclosure, transparency, and accountability[86]. - The company has established an audit committee, nomination committee, and remuneration committee as part of its corporate governance practices[104]. - The audit committee consists of three independent non-executive directors and has reviewed the financial performance for the year 2020[104]. Environmental Responsibility - The group is committed to protecting the environment and fulfilling social responsibilities while adhering to strict corporate governance standards[149]. - The environmental policy includes monitoring compliance with applicable environmental laws and promoting an eco-friendly culture among employees[164]. - The company has not recorded any violations of environmental laws during the reporting period[175]. - The company aims to maintain a zero-violation record in hazardous waste management, reflecting its commitment to environmental responsibility[182]. Employee Management - The total employee cost for the year was approximately HKD 67,551,000, an increase from HKD 48,739,000 in the previous year[67]. - The company employed a total of 129 full-time employees as of December 31, 2020, down from 143 in 2019[67].
中国生物科技服务(08037) - 2020 - 年度财报